Avicenna journal of medical biotechnology · 2026
Designing a Novel Immunotoxin against Prostate Cancer based on PE40 Toxin: An In silico Approach.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Azdoo Sadaf, Taheri-Anganeh Mortaza, Ahmadi Khadijeh, Ghadimi Moghadam Abdolkarim, Movahedpour Ahmad, Jamshidi Ali
Аннотация
BACKGROUND: Prostate cancer, is the second most prevalent malignant tumor and fifth leading cause of cancer-related death among men worldwide. Patients suffer from adverse side effects and low efficacy of traditional therapeutic approaches. At present, cancer-targeted therapy is a fascinating strategy of cancer therapy re-search via employing immunotoxins, which is a fusion of a targeting molecule and a killer toxin that can recognize a specific antigen on cancerous cells and trigger cell death.
METHODS: This study used a prostate-specific scFv and a truncated version of Pseudomonas-exotoxin to design a novel immunotoxin. After the construct design, the construct's secondary structure, physicochemical features, and allergenicity were predicted by SOPMA, Protparam, and AllergenFP, respectively. Then, the 3D structure was built via ITASSER. ProSa-web and PROCHECK were used for structure validation. The 3D model was docked by Cluspro, and molecular dynamics was carried out by GROMACS.
RESULTS: The results showed that the average RMSF value for the PSMA receptor was 0.478 Å, and for the designed toxin was 0.292 Å. The low range of changes indicates the stability of the complex during the simulation.
CONCLUSION: The present results indicate that the designed immunotoxin is structurally stable, non-allergenic, and capable of binding PSMA, suggesting it as a potential candidate for further experimental evaluation.
METHODS: This study used a prostate-specific scFv and a truncated version of Pseudomonas-exotoxin to design a novel immunotoxin. After the construct design, the construct's secondary structure, physicochemical features, and allergenicity were predicted by SOPMA, Protparam, and AllergenFP, respectively. Then, the 3D structure was built via ITASSER. ProSa-web and PROCHECK were used for structure validation. The 3D model was docked by Cluspro, and molecular dynamics was carried out by GROMACS.
RESULTS: The results showed that the average RMSF value for the PSMA receptor was 0.478 Å, and for the designed toxin was 0.292 Å. The low range of changes indicates the stability of the complex during the simulation.
CONCLUSION: The present results indicate that the designed immunotoxin is structurally stable, non-allergenic, and capable of binding PSMA, suggesting it as a potential candidate for further experimental evaluation.